[QUOTE=ashleyk;1273428]This is interesting but years? away.
It wont happen because its the Market Economy that dictates were to spend money, reality is your worth more on the global market ill than not.
''Its beyond interesting because it works'' and I am living talking walking proof of it.
I had no aspirations beyond proving the science to myself.Professor Gill worked his butt off for ten years to develop a delivery device,that did what it was meant to doand more.
As well but incidental to the device and PD it is now delivering chemotherapy to brain tumours directly.A huge impact will be made by the device alone.
Still for us its years away if it makes it at all.I have learned more from this forum and fellow sufferers,than from any scientific journal.Im well educated but Ive worn a hole in my soap box and broken every bone in my body falling of it.Were to now I honestly dont know as yet
I wonder if any of you remember Bryn williams opening words
A LONG AGO WPC
Urgency. Ladies and gentlemen, Urgency.
The fierce urgency of now.
Now is the time to realise the promises of science.
Now is the time to bring our urgency to bear and deliver a future of hope for the victims of this disease.
Now is the time for a steady hand, a strong voice and a keen sense of smell for the opportunities that await us.
GDNF Trial Results Published | The Cure Parkinson's Trust
Key Findings
[LIST][*]This was the first randomised clinical trial in Parkinsons using an innovative delivery mechanism to administer a neurotrophic factor to a region deep inside the brain called the putamen. The device is now being used in two new trials[*]The drug was safe with 99% compliance for infusions paving way for further research.[*]PET scans showed the method of administration affords spatial delivery of GDNF sufficient to achieve biological effect across the entire putamen.[*]By trial end, most participants saw meaningful clinical improvement although the evidence was deemed inconclusive as the trial in its final stages was not double blind without comparison group.[*]A number of participants felt that the therapy had beneficial effects. The study team believe further investigation of GDNF is required - exploring increased dose and delivered over a longer period of time.[*]Further testing of GDNF in a larger-scale study and including the use of higher doses is required to definitively determine whether GDNF has a future role as a neurorestorative treatment.